Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Why RAPT Therapeutics Stock Is Surging Today

RAPT Therapeutics Inc (NASDAQ: RAPT) shares are trading higher by 95% at $36.19 after the company reported topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis.
byHenry Khederian
June 14, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

RAPT Therapeutics Inc (NASDAQ:RAPT) shares are trading higher by 95% at $36.19 after the company reported topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis. Read more here…

RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. 

RAPT Therapeutics pipeline of products includes FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Why Nio Stock Is Falling Today

By Adam Eckert
Today, 4:11 AM
NIO Inc (NYSE: NIO) shares are trading lower Monday amid a resurgence in COVID-19 cases in China. Recent outbreaks have caused casinos, among other businesses, to close in Macau. Fears that new lockdowns could be implemented are crippling China-based stocks today. 

BABA

Read More

The Crisis In Housing, Part 4: Waiting For A Crypto Future

By Phil Hall
Today, 4:11 AM
Compared to other sectors of the wider economy, the housing and mortgage industries have traditionally been slower to embrace cutting-edge technologies and digital solutions. A myriad of reasons explain this pokey response to evolving change, ranging from the sector’s conservative risk tolerance to a lack of standardization in many evolving technologies.

$DOGE